Lyndra Therapeutics president and COO Jessica Ballinger (L) and CMO Rich Scranton

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

With a Phase III tri­al now un­der­way for a once-week­ly, long-act­ing ver­sion of the an­tipsy­chot­ic med risperi­done, Lyn­dra Ther­a­peu­tics is eye­ing a large Se­ries D to push it through a 2025 NDA fil­ing with the goal of tak­ing it to mar­ket in 2026.

The biotech has closed the first tranche of the round, slight­ly over $20 mil­lion with the help of in­sid­ers, and is an­gling for $180 mil­lion to­tal, Jes­si­ca Ballinger, pres­i­dent and op­er­at­ing chief, told End­points News on the side­lines of this year’s BIO con­fab in Boston. Lyn­dra is cap­i­tal­iz­ing on slow-re­lease tech­nol­o­gy out of the MIT lab of Bob Langer, who is known in many cir­cles but more broad­ly for work on the de­liv­ery tech for the mR­NA Covid-19 vac­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.